Document Detail

New therapeutic targets for the development of positive inotropic agents.
MedLine Citation:
PMID:  22127109     Owner:  NLM     Status:  In-Data-Review    
Heart failure is associated with significant morbidity and mortality despite significant advances in therapies developed for it. Because impaired cardiac contractility plays a central role in systolic HF, drugs increasing cardiac contractility (positive inotropics) have been widely used for HF treatment. Conventional inotropics that increase cAMP and intracellular Ca2+ levels improve symptoms and hemodynamics, but also increase myocardial oxygen demands, cardiac arrhythmias, and mortality, which decreases their overall therapeutic benefit-risk ratio in HF. Thus, we need new inotropic agents with different mechanisms of action that improve clinical outcomes. This review describes the mechanism of action and preliminary clinical results obtained with these new investigational positive inotropic agents.
Juan Tamargo; Juan Duarte; Ricardo Caballero; Eva Delpón
Related Documents :
22564599 - Preischemic treatment with melatonin attenuates liver reperfusion-induced impairment of...
2335849 - Effects of a thromboxane a2 synthetase inhibitor on ventricular fibrillation threshold ...
2789099 - Bepridil versus nifedipine for ventricular tachycardia induced in the late postinfarcti...
22175759 - Focal initiation of sustained and nonsustained ventricular tachycardia in a canine mode...
21766159 - Bms309403 directly suppresses cardiac contractile function.
1155339 - Effect of practolol on left ventricular dimensions during coronary occlusion.
9505019 - Coronary artery bypass surgery without cardiopulmonary bypass: short- and mid-term resu...
9628379 - Should coronary artery bypass grafting be performed at the same time as repair of a pos...
1948969 - Surgical treatment of left-ventricular outflow-tract obstruction guided by intraoperati...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Discovery medicine     Volume:  12     ISSN:  1944-7930     ISO Abbreviation:  Discov Med     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101250006     Medline TA:  Discov Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  381-92     Citation Subset:  IM    
Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, 28040, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Field cancerization in Barrett's esophagus.
Next Document:  Advances in the understanding and treatment of colorectal cancer.